CM Life Sciences III Inc. Just Filed Its Quarterly Report: 15. NET LOSS PER SHA...

15. NET LOSS PER SHARE

The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):

Three months ended June 30, 

Six months ended June 30, 

    

2023

    

2022

    

2023

    

2022

Net loss

$

(72,956)

$

(82,546)

$

(155,507)

$

(61,820)

Weighted average common shares outstanding, basic and diluted

482,119,498

473,058,458

481,070,872

471,849,487

Net loss per share, basic and diluted

$

(0.15)

$

(0.17)

$

(0.32)

$

(0.13)

The Company’s potentially dilutive securities, which include Warrants, Earn-Out Shares, options to purchase common stock, unvested restricted stock units and unvested restricted common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:

Three months ended June 30, 

 

Six months ended June 30, 

    

2023

    

2022

    

2023

    

2022

Outstanding Warrants

 

19,733,290

 

19,733,290

19,733,290

 

19,733,290

Outstanding stock options

 

36,297,461

 

40,400,744

36,297,461

 

40,400,744

Unvested restricted stock units

4,557,374

4,557,374

Earn-Out Shares

50,000,000

50,000,000

50,000,000

50,000,000

Unvested restricted stock

 

4,374,910

 

13,927,410

4,374,910

 

13,927,410

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever CM Life Sciences III Inc. makes a similar move, sign up!

Auto Refresh

Feedback